|Reata Pharmaceuticals, Inc. Announces Positive Data From Part One of Moxie Trial of Omaveloxolone for Friedreich’s Ataxia|
Omaveloxolone Induced Nrf2 and Improved Mitochondrial and Neurological Function
Company Planning to Initiate Part 2 of Trial During the Second Half of 2017
Data Presentation and Conference Call Scheduled for
"We are greatly appreciative of Reata, the clinical investigators, and the study volunteers for conducting and participating in a well-designed and robust dose-escalation study. We find these results to be very exciting, and they are the ideal outcome for an early Phase 2 study. They exceed expectations in terms of safety and by demonstrating dose-dependent and clinically meaningful activity that correlated with biological activity," said
The complete data will be presented by Dr.
Study Design and Key Efficacy Endpoints
Part 1 of MOXIe was a double-blind, randomized, placebo-controlled, dose-ranging, multi-center, international trial that enrolled a total of 69 FA patients to receive placebo (n = 17) or omaveloxolone (n = 52) at doses of 5 mg to 300 mg given orally, once-daily for 12 weeks. Part 1 of MOXIe was designed to identify a safe and clinically active dose of omaveloxolone to study in Part 2. Part 1 randomized eight to 16 patients in a 3:1 ratio of omaveloxolone to placebo across seven dose levels and was not powered to demonstrate statistical separation from placebo at any single dose level. The study assessed pharmacodynamic measures of Nrf2 activation and mitochondrial function, as well as two key efficacy endpoints: a measure of muscle function, peak work during maximal exercise testing (primary endpoint), and a measure of neurological function that has been the primary endpoint for prior registrational studies in FA, the mFARS (secondary endpoint).
The MOXIe Part 1 dose-escalation trial identified 160 mg of omaveloxolone as the optimal dose associated with pharmacodynamic measures of Nrf2 induction and improvements in mitochondrial function. Nrf2, the target of omaveloxolone, is suppressed in FA patients leading to impaired mitochondrial function. Impaired mitochondrial function in FA patients has been shown to correlate with impaired neurological function as assessed by the mFARS. Dose-dependent induction of Nrf2 transcriptional target proteins, ferritin and gamma-glutamyl transferase (GGT), was observed at doses as low as 20 mg and reached statistical significance from baseline at doses of 80 mg and higher. Two markers of cellular metabolism, aspartate aminotransferase (AST) and creatine kinase (CK), were monitored to assess improvements in mitochondrial function. AST delivers substrate to the mitochondria for energy production as part of the malate shuttle, and CK is involved in the utilization of adenosine triphosphate (ATP) throughout cells. Dose-dependent modulation of AST and CK was observed and statistically significant changes from baseline were observed at doses of 80 and 160 mg.
Omaveloxolone improved neurological function in a dose- and time-dependent manner as assessed by mFARS. Across all doses, omaveloxolone significantly improved (by reducing) mFARS by 2.5 points from baseline (p<0.001) and by 1.1 points versus placebo (non-significant). At the 160 mg dose, omaveloxolone improved mFARS by 3.8 points versus baseline (p=0.0001) and by 2.3 points versus placebo (p=0.06).
Omaveloxolone produced greater improvements in mFARS in patients that did not have a preexisting musculoskeletal foot deformity that causes high arched feet, called pes cavus. Presence of this deformity can affect the patients' ability to use their legs, walk, and perform neurologic and exercise testing independent of their ataxia. In patients without this foot deformity, omaveloxolone significantly improved mFARS by 3.3 points from baseline (p<0.001) and by 1.7 points from placebo (non-significant). In this group, the maximum effect on mFARS was observed at the 160 mg dose level. At this dose, omaveloxolone improved mFARS by 6.0 points from baseline (p<0.0001) and by 4.4 points versus placebo (p=0.01). Twelve weeks of treatment at the optimal dose of 160 mg resulted in a placebo-corrected improvement in neurological function that is equivalent to recovering approximately one to two years' of disease progression.
Across all patients, omaveloxolone did not improve peak work as measured during the maximal exercise test. The Company received reports from clinical sites that patients with pes cavus were not able to reach peak muscle exhaustion during the maximal exercise test due to pain associated with their foot deformity. In the subset of patients without the pes cavus foot deformity, across all doses omaveloxolone increased peak work by 6.5 watts relative to baseline (p=0.002) and by 4.3 watts versus placebo (non-significant). In these patients, omaveloxolone produced a dose- and time-dependent increase in peak work, and the maximum effect on peak work was observed at the 160 mg dose level. At this dose, omaveloxolone increased peak work 11.5 watts from baseline (p=0.03) and 9.0 watts versus placebo (non-significant), which is a 13% relative improvement.
Safety and Tolerability
The trial was overseen by an independent data safety monitoring board (DSMB). No safety concerns were identified by the DSMB. Only two serious adverse events were reported, and both events occurred in placebo-treated patients. The most common adverse events in excess to placebo in the omaveloxolone group were upper respiratory tract infections and nasopharyngitis, which were generally mild in severity. Omaveloxolone was well-tolerated with only a single discontinuation in a 40 mg patient who developed a skin rash. One placebo patient discontinued prematurely due to withdrawal of consent.
Design of Part 2 of MOXIe
The Company plans to initiate Part 2 of the MOXIe trial during the second half of 2017. Part 2 of MOXIe will be a double-blind, randomized, placebo-controlled, multi-center, international trial designed to evaluate the safety and efficacy of omaveloxolone in patients with FA. The trial will enroll approximately 100 FA patients randomized evenly to either 150 mg of omaveloxolone or placebo. A 150 mg dose of omaveloxolone should produce similar systemic exposure while reducing the number of capsules per administration when compared to a 160 mg dose. Patients will be stratified by pes cavus status, and the proportion of pes cavus patients will be limited. Study drug will be administered orally, once daily for 24 weeks. The proposed primary endpoint of the study will be the change from baseline in mFARS of omaveloxolone compared to placebo at 24 weeks. A key secondary endpoint of the study will be the change from baseline in peak work during maximal exercise testing compared to placebo at 24 weeks. The study will also assess changes in the FA activities of daily living scale (ADL), the 25-foot timed walk test, the 9-hole peg test, the frequency of falls, and SF-36 scores.
In selecting mFARS as the primary endpoint for the study, the Company has worked closely with
During 2014, the Division provided the Company with guidance regarding the clinical endpoints and other design elements of MOXIe. The Division asked the Company to confirm that it planned to use the mFARS as an endpoint in MOXIe and stated that the mFARS would likely be considered an intermediate clinical endpoint that could support accelerated approval for drugs treating serious or life-threatening illnesses under Subpart H of the
Presentation of MOXIe Data
The complete data will be presented by Dr.
Reata management will host a call at
About Friedreich's Ataxia
FA is a rare, degenerative, life-shortening neuro-muscular disorder that affects children and adults and involves the loss of strength and coordination usually leading to wheelchair use; diminished vision, hearing and speech; scoliosis (curvature of the spine); increased risk of diabetes; and a life-threatening heart condition. Currently, there are no